Hydroxypropyl Betadex – Excipient for improving the solubility and stability of injectable formulations

1. General introduction to Hydroxypropyl Betadex 

Hydroxypropyl-β-cyclodextrin (HP-β-CD) is a semisynthetic derivative of β-cyclodextrin, produced by introducing hydroxypropyl groups onto the hydroxyl groups of the β-cyclodextrin molecule. This structural modification significantly enhances its aqueous solubility, reduces nephrotoxicity, and minimizes the tendency to crystallize compared with native β-cyclodextrin.

Owing to its ability to form inclusion complexes with a wide range of poorly water-soluble drug substances, HP-β-CD has become one of the most widely used excipients in injectable pharmaceutical formulations. It enhances the solubility and chemical stability of hydrophobic active pharmaceutical ingredients (APIs) without requiring large amounts of organic solvents or surfactants.

HP-β-CD has been accepted for use in numerous parenteral drug products by major regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Today, multiple commercially available injectable products formulated with HP-β-CD are marketed worldwide.

2. Structure and Properties

HP-β-CD retains the characteristic truncated cone structure of cyclodextrins, consisting of:

• A hydrophobic inner cavity
• A hydrophilic outer surface
• An average molecular weight of approximately 1,300–1,500 Da, depending on the degree of hydroxypropyl substitution

The introduction of hydroxypropyl groups provides several advantages:

• Increases aqueous solubility from approximately 18 mg/mL for native β-cyclodextrin to over 500–600 mg/mL
• Reduces the tendency to crystallize
• Decreases interactions with membrane cholesterol
• Lowers the risk of nephrotoxicity
• Makes it suitable for intravenous infusion and injection formulations

Mechanism of Action

The hydrophobic cavity of HP-β-CD can encapsulate part or all of a hydrophobic drug molecule through non-covalent interactions, forming a reversible inclusion complex.

API + HP-β-CD ⇌ API–HP-β-CD Inclusion Complex

This dynamic equilibrium maintains a balance between the free drug and the complexed drug. Following parenteral administration, the inclusion complex rapidly dissociates as the drug is absorbed or distributed, releasing the active pharmaceutical ingredient to exert its therapeutic effect.

3. Advantages of HP-β-CD in Injectable Formulations

• Enhanced apparent solubility: HP-β-CD significantly increases the apparent solubility of poorly water-soluble drug substances by forming reversible inclusion complexes. This helps prevent drug precipitation, maintain a clear solution, increase the concentration of dissolved drug, and improve the bioavailability of parenteral formulations. Depending on the chemical structure of the drug and the stability constant of the inclusion complex, solubility may increase by several-fold to several hundred-fold.
• Improved chemical stability: By encapsulating drug molecules within its hydrophobic cavity, HP-β-CD protects them from degradation caused by oxygen, light, moisture, and metal ions. This protective effect enhances the stability of chemically sensitive active pharmaceutical ingredients (APIs) in injectable formulations and contributes to a longer shelf life.
• Reduced injection-site irritation: Partial encapsulation of the drug within the HP-β-CD cavity decreases the concentration of free drug in direct contact with tissues. As a result, HP-β-CD can reduce local tissue irritation, minimize injection pain, and lower the risk of drug precipitation at the injection site.
• Reduced need for organic solubilizers: The use of HP-β-CD can substantially reduce or eliminate the need for organic co-solvents and solubilizing agents such as ethanol, propylene glycol, polyethylene glycol, and benzyl alcohol. This helps minimize injection discomfort, tissue irritation, and the potential toxicity associated with these excipients.
• Excellent biocompatibility:Compared with native β-cyclodextrin, HP-β-CD exhibits significantly lower hemolytic activity and nephrotoxicity. It is generally well tolerated when administered parenterally at appropriate doses and has been widely used in approved injectable drug products.
• Good compatibility with other excipients: HP-β-CD is compatible with a wide range of active pharmaceutical ingredients and pharmaceutical excipients, providing greater formulation flexibility and facilitating the development of optimized injectable products.

4. Applications of Hydroxypropyl Betadex

HP-β-CD is widely used in injectable formulations for the following purposes:

• Enhancing drug solubility
• Protecting and stabilizing active pharmaceutical ingredients (APIs)
• Reducing injection-site irritation and pain
• Extending product shelf life

In addition to intravenous injections, HP-β-CD is also used in:

• Intramuscular injections
• Subcutaneous injections
• Sterile ophthalmic solutions
• Lyophilized injectable formulations
• Biopharmaceutical formulations requiring enhanced API stability

Representative APIs suitable for HP-β-CD Formulation:

5. Commercial products utilizing Hydroxypropyl Betadex

6. Product contact information 

For technical documentation, COA, DMF support, product samples, or formulation consultation regarding Hydroxypropyl Betadex applications in pharmaceutical, cosmetic, and nutraceutical formulations, please contact us:

• Hotline: +84 (0) 834 560 500
• Email: director@biorichgroup.com
• Website: www.biorichgroup.com
• Sample & COA Requests: Contact the Biorich team to receive evaluation samples, quality documentation, and technical support for your specific product development needs.